TRACON Pharmaceuticals Inc
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 Ig… Read more
TRACON Pharmaceuticals Inc (TCON) - Net Assets
Latest net assets as of June 2024: $-3.09 Million USD
Based on the latest financial reports, TRACON Pharmaceuticals Inc (TCON) has net assets worth $-3.09 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.40 Million) and total liabilities ($10.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.09 Million |
| % of Total Assets | -41.74% |
| Annual Growth Rate | N/A |
| 5-Year Change | -129.99% |
| 10-Year Change | N/A |
| Growth Volatility | 313.97 |
TRACON Pharmaceuticals Inc - Net Assets Trend (2012–2023)
This chart illustrates how TRACON Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for TRACON Pharmaceuticals Inc (2012–2023)
The table below shows the annual net assets of TRACON Pharmaceuticals Inc from 2012 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-809.00K | +88.69% |
| 2022-12-31 | $-7.15 Million | -161.05% |
| 2021-12-31 | $11.71 Million | -53.28% |
| 2020-12-31 | $25.07 Million | +829.28% |
| 2019-12-31 | $2.70 Million | -87.42% |
| 2018-12-31 | $21.44 Million | +26.23% |
| 2017-12-31 | $16.99 Million | -40.05% |
| 2016-12-31 | $28.34 Million | -8.53% |
| 2015-12-31 | $30.98 Million | +196.28% |
| 2014-12-31 | $-32.17 Million | -26.95% |
| 2013-12-31 | $-25.34 Million | -43.49% |
| 2012-12-31 | $-17.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to TRACON Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22083600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $44.00K | % |
| Other Components | $239.65 Million | % |
| Total Equity | $-809.00K | 100.00% |
TRACON Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of TRACON Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Panaxia Labs Israel Ltd
TA:HROD
|
$107.94K |
|
K-W
NYSE:K-W
|
$107.94K |
|
TRIPADVISOR
BE:T6A
|
$108.01K |
|
Kalium Lakes Ltd
AU:KLL
|
$108.08K |
|
VILKYSKIU PIENINE (UDW.SG)
STU:UDW
|
$107.79K |
|
Centrais Electricas Brasileiras S.A.- Eletrobr?!s American Depositary Shares (Each representing one Preferred Share)
NYSE:EBRB
|
$107.72K |
|
FRBP
PINK:FRBP
|
$107.68K |
|
African Agriculture Holdings Inc
NASDAQ:AAGRW
|
$107.62K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TRACON Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -7,151,000 to -809,000, a change of 6,342,000.
- Net loss of 3,588,000 reduced equity.
- New share issuances of 8,063,000 increased equity.
- Other factors increased equity by 1,867,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.59 Million | -443.51% |
| Share Issuances | $8.06 Million | +996.66% |
| Other Changes | $1.87 Million | +230.78% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares TRACON Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-3.60 | $0.03 | x |
| 2013-12-31 | $-51.62 | $0.03 | x |
| 2014-12-31 | $-2.69 | $0.03 | x |
| 2015-12-31 | $2.79 | $0.03 | x |
| 2016-12-31 | $2.24 | $0.03 | x |
| 2017-12-31 | $10.11 | $0.03 | x |
| 2018-12-31 | $7.96 | $0.03 | x |
| 2019-12-31 | $0.89 | $0.03 | x |
| 2020-12-31 | $55.81 | $0.03 | x |
| 2021-12-31 | $13.58 | $0.03 | x |
| 2022-12-31 | $-6.84 | $0.03 | x |
| 2023-12-31 | $-0.49 | $0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TRACON Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -29.79%
- • Asset Turnover: 1.19x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-133.65%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.16 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.17 Million |
| 2014 | 0.00% | -189.24% | 0.09x | 0.00x | $-3.59 Million |
| 2015 | -78.80% | -308.83% | 0.15x | 1.73x | $-27.51 Million |
| 2016 | -95.31% | -783.07% | 0.08x | 1.61x | $-29.84 Million |
| 2017 | -112.46% | -218.20% | 0.24x | 2.13x | $-20.80 Million |
| 2018 | -163.04% | -1165.30% | 0.07x | 1.90x | $-37.10 Million |
| 2019 | -839.81% | 0.00% | 0.00x | 6.72x | $-22.93 Million |
| 2020 | -69.10% | -5007.51% | 0.01x | 1.49x | $-19.83 Million |
| 2021 | -245.23% | -8302.31% | 0.01x | 2.27x | $-29.90 Million |
| 2022 | 0.00% | -325.69% | 0.46x | 0.00x | $-28.60 Million |
| 2023 | 0.00% | -29.79% | 1.19x | 0.00x | $-3.51 Million |
Industry Comparison
This section compares TRACON Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TRACON Pharmaceuticals Inc (TCON) | $-3.09 Million | 0.00% | N/A | $107.83K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |